Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165458 | 0.92 | — | — | |
| SCHEMBL17461586 | 0.83 | TSHR (0.33) | LMNATSHRCYP2C9 | |
| SCHEMBL28396141 | 0.82 | TSHR (0.32) | TSHR | |
| SCHEMBL145637 | 0.82 | TDP1 (0.38) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL487683 | 0.82 | TDP1 (0.38) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10277718 | 0.82 | TDP1 (0.38) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6440366 | 0.80 | TDP1 (0.33) | TSHR | |
| SCHEMBL28349044 | 0.80 | TDP1 (0.33) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL16763465 | 0.79 | TDP1 (0.42) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28762380 | 0.79 | ALOX15 (0.52) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214949-A1 | TRIAZINE CARBAMATE CROSSLINKER | ALLNEX USA INC. (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4532211-A1 | TRIAZINE CARBAMATE CROSSLINKER | Allnex USA Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119255916-A | Triazine carbamate cross-linking agents | 湛新美国股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023230122-A1 | TRIAZINE CARBAMATE CROSSLINKER | ALLNEX USA INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282859-A1 | TRIAZINE CARBAMATE CROSSLINKER | Allnex USA Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-1138327-A | Etherified alkyl or arylcarbamoylmethylated aminotriazines and curable compositions containing same | PPG INDUSTRIES INC (US) | 1996-12-18 | — | — | CN | disclosed |
| EP-0730585-A1 | ETHERIFIED ALKYL OR ARYLCARBAMYLMETHYLATED AMINOTRIAZINES AND CURABLE COMPOSITIONS CONTAINING THE SAME | PPG INDUSTRIES, INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5545696-A | FILM FORMERS IN COATINGS | PPG INDUSTRIES, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5536835-A | Etherified alkyl or arylcarbamylmethylated aminotriazines and curable compositions containing the same | PPG INDUSTRIES, INC. (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995014677-A1 | ETHERIFIED ALKYL OR ARYLCARBAMYLMETHYLATED AMINOTRIAZINES AND CURABLE COMPOSITIONS CONTAINING THE SAME | PPG INDUSTRIES, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214949-A1 | TRIAZINE CARBAMATE CROSSLINKER | SCO2, CBR3, CBR1 | ALOX15 999/4885CHRNB2 770/4885CHRNA4 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.